One study showed that ATRi with small molecule inhibitors or ATR-targeted siRNA augmented expression of PD-L1 in murine and human small cell lung cancer (SCLC) cell lines via the cGAS/STING pathway [42]. This evidence concerns the gene CGAS and small cell lung carcinoma.